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Background/Aims: Hepatic hydrothorax in patients with decompensated liver cirrhosis is a challenging problem. 
Treatment with diuretics and intermittent thoracentesis can be effective in selected patients. However, there are few 
effective therapeutic options in patients who are intolerant of these therapies. This study investigated the clinical 
usefulness of chemical pleurodesis with or without video-assisted thoracoscopic surgery (VATS) for patients with 
refractory hepatic hydrothorax. Methods: Eleven consecutive patients with refractory hepatic hydrothorax who underwent 
chemical pleurodesis with or without VATS between July 2007 and February 2011 were enrolled in this study. The medical 
records and radiologic imagings of these patients were thoroughly reviewed. Results: The median number of chemical 
pleurodesis sessions performed was 3 (range: 2-10). Successful pleurodesis was achieved in 8 of the 11 patients (72.7%), 
5 (62.5%) of whom remained asymptomatic and hydrothorax free for a median follow-up of 16 weeks (range: 2-52 weeks). 
Complications were low-grade fever/leukocytosis (n=11, 100%), pneumonia (n=1, 9.1%), pneumothorax (n=4, 36.4%), 
azotemia/acute renal failure (n=6, 54.6%), and hepatic encephalopathy (n=4, 36.4%). Five patients were suspected as 
having procedure-related mortality (45.5%) due to the occurrence of acute renal failure with hepatic failure. The overall 
survival was significantly longer in the success group than in the non-success group. Conclusions: Although chemical 
pleurodesis may improve the clinical symptoms and the radiologic findings in as many as 72.7% of patients with refractory 
hepatic hydrothorax, a significantly high prevalence of procedure-related morbidity and mortality hinders the routine 
application of this procedure for such patients. (Korean J Hepatol 2011;17:292-298)
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INTRODUCTION
Hepatic hydrothorax is defined as a significant pleural 
effusion, usually greater than 500 mL, in a patient with liver 
cirrhosis but no primary cardiac or pulmonary diseases.
1,2 In 
patients with hepatic hydrothorax, even a modest volume of 
pleural fluid can cause respiratory symptoms, in contrast to 
ascites, where a large volume can be well tolerated.
Hepatic hydrothorax is a relatively uncommon complication 
of end-stage liver with an estimated prevalence of 5-10%
 
among cirrhotic patients.
1-4 In spite of the numerous case 
reports describing clinical features and treatments for hepatic 
hydrothorax the current knowledge of this complication of 
cirrhosis is limited. Unfortunately the pathogenesis and 
therapy of hepatic hydrothorax have not been appropriately 
studied, therefore, proper guidelines on therapy based on 
good evidence have been difficult to establish.
The aim of current study is to examine the treatment 
outcomes of the 11 patients with refractory hepatic hydrothorax 
who underwent chemical pleurodesis with or without 
video-assisted thoracoscopic surgery (VATS).Woo Jin Lee, et al. Pleurodesis for hepatic hydrothorax  293
PATIENTS AND METHODS
Patients
Eleven consecutive patients with refractory hepatic 
hydrothorax and decompensated liver cirrhosis who 
underwent chemical pleurodesis with or without VATS in 
our institution between July 2007 and February 2011 were 
included. The Child-Turcotte-Pugh (CTP) class and etiology 
of cirrhosis was documented in all patients. All 11 patients 
had failed medical treatment because diuretics and other 
modes of therapy had not led to symptomatic improvement 
or caused electrolytes disturbances or impairment in renal 
function. Average diuretic dosages in the study population 
were spironolactone 200 mg/day and furosemide 80 mg/day. 
Of 11 patients, 10 (90.9%) had coexisting ascites and the 
amount of ascites examined by abdominal ultrasonography 
were small in 9 patients and moderate in 1 patient, respectively. 
The diuretic treatment applied to these patients for the 
management of symptomatic hydrothorax was sufficient for 
the control of ascites. A medical history, physical examination, 
laboratory findings, and radiologic imagings including chest 
X-ray, and computed tomographic (CT) scans of the chest 
and abdomen were thoroughly reviewed. Echocardiography 
was performed to measure left ventricular function in all 11 
patients. Abdominal ultrasound or CT scans were performed 
in all 11 patients to examine the liver for size and structure 
and to determine the presence of ascites. Simultaneously 
with abdominal ultrasound, a Doppler study for patency of, 
and flow in, the hepatic and portal venous systems was also 
performed. Prior to the chemical pleurodesis with or without 
VATS, a diagnostic thoracentesis (approximately 40-50 mL 
of pleural fluid) was performed in all 11 patients for con-
firmation of diagnosis and to exclude alternative diagnoses. 
Diagnostic tests of pleural fluid to be ordered included cell 
count, Gram stain and culture of the pleural fluid in blood 
culture bottles and fluid protein, albumin, lactative dehydro-
genase and bilirubin. Other tests in pleural fluid that would 
be appropriate depending on the clinical circumstance 
include triglyceride, pleural pH, adenosine deaminase, and 
polymerase chain reaction (PCR) for mycobacterium, 
amylase, and cytology to exclude chylothorax, empyema, 
tuberculosis, pancreatitis and malignancy, respectively. This 
study was conducted in accordance with the principles of the 
Declaration of Helsinki. Our study protocol obtained 
approval of the Ethics Committee of Kangbuk Samsung 
Hospital.
VATS and chemical pleurodesis 
VATS was performed in two patients with the intent to 
provide chemical pleurodesis. The remaining 9 patients 
underwent only chemical peurodesis by tube thoracostomy. 
The agents used in chemical peurodesis were talc in 3 
patients (27.3%), taurolidine in 2 patients (18.2%) and viscum 
album in 6 patients (54.25%). The processes of chemical 
pelurodesis were performed as previously defined.
5 VATS 
operative procedure was as follows. Patients received 
general anesthesia. The rigid pleural effusion was drained 
using by a 5-mm rigid thoracoscopy. It was sent for body 
fluid chemistry, cytology and culture. If the fenestrations of 
hemidiaphragm were noticed during the thoracoscopic 
observation, they were closed using thoracoscopic technique 
with suture. The insufflated slcerosing agents used in VATS 
were talc (20 g)+bleomycin (30 mg) in one patient and 
taurolidine (10 g)+bleomycin (30 mg) in another patient. 
Definitions
Successful pelurodesis was defined by a patient who had 
no longer dyspnea symptoms and had a chest roentgenogram 
that did not show pleural effusion at 1 month after the 
termination of VATS with chemical pleurodesis or chemical 
pleurodesis only. The definition for refractory hepatic 
hydrothorax has not been properly established. We adopted 
the definition of refractory hepatic hydrothorax as a 
symptomatic hepatic hydrothorax which was refractory to 
conventional treatments for hepatic hydrothorax, such as 
salt restriction, maximum tolerable dosage of diuretics, 
repeated thoracentesis and pleural drainage. Procedure 
related morbidity and mortality were defined as the 
occurrences of any complication and/or death within 1 
month relevant to the adoption of chemical pleurodesis with 
or without VATS for the management of refractory hepatic 
hydrothorax in our enrolled patients.
Statistical methods
Mann-Whitney U-test for continuous variables and Fisher’s 
exact test for categorical variables were performed. The 
comparison of the cumulative survival rate between success 
and non-success group was performed using a log-rank test 
with Kaplan-Meier analysis. Data were analyzed using 294  The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
Table 1. Baseline characteristics of the subjects
Characteristics Values
Number of patients
Median age (range, years)
Male gender (%)
Causes of liver cirrhosis (%)
Alcohol
HBV
HCV
Cryptogenic
Site of pleural effusion (%)
Right
Left
Sclerosing agents for pleurodesis (%)
Talc
Taurolidine
Viscum album
Treatment method (%)
Chemical pleurodesis only
Chemical pleurodesis+VATS
Median sessions of pleurodesis (range)
Child-Turcotte-Pugh class (%)
B
C
Median MELD score (range)
Success of treatment
*
Yes
No
Median follow-up periods (range, weeks)
11
63 (38-84)
6 (54.5)
1( 9 . 1 )
4 (36.4)
4 (36.4)
2 (18.2)
11 (100.0)
0( 0 )
3 (27.3)
2 (18.2)
6 (54.5)
9 (81.8)
2 (18.2)
3( 2 - 1 0 )
2 (18.2)
9 (81.8)
16 (9-21)
8 (72.7)
3 (27.3)
16 (2-52)
* Success of treatment was defined by a patient who had no 
longer dyspnea symptoms and had a chest roentgenogram that 
did not show pleural effusion at 1 month after the termination 
of VATS with chemical pleurodesis or chemical pleurodesis 
only. 
SD, standard deviation; HBV, hepatitis B virus; HCV, hepatitis 
C virus; VATS, video- assisted thoracoscopic surgery; MELD, 
model for end stage liver disease.
PASW software package (version 18.0; SPSS, Inc., Chicago, 
IL, USA). P-values less than 0.05 were considered significant.
RESULTS
A total of 11 patients with refractory hepatic hydrothorax 
were included. Median (range) age of the patients was 63 
(38-84) years and 6 (54.5%) patients were male. The 
etiologies of liver cirrhosis were HBV (n=4, 36.2%), HCV 
(n=4, 36.4%), alcoholic (n=1, 9.1%) and cryptogenic (n=2, 
18.2%). Nine (81.8%) and 2 patient were CTP class C and 
B, respectively. All the patients have right sided pleural 
effusion refractory to medical therapy. The median (range) 
sessions of chemical pleurodesis were 3 (2-10) times. Nine 
patients underwent only chemical pleurodesis via chest tube 
and two patients underwent chemical pleurodesis with 
VATS (Table 1). During the chemical pleurodesis with or 
without VATS, tolerable medical treatments such as low salt 
diet, diuretics and chest tube drainage were maintained. 
Diaphragmatic defects were not observed in the patients 
during the VATS procedure.
Successful pleurosdesis was achieved in 8 of 11 patients 
(72.7%, Table 1). Representative radiologic findings of chest 
X-ray and CT were shown in Figure 1. By Kaplan-Meier 
analysis with log rank comparison, the overall survival was 
significantly longer in the success group than the 
non-success group (P<0.01). Five (62.5%) of the patients in 
the success group remained asymptomatic and hydrothorax 
free at a median follow-up of 16 (2-52) weeks after the 
procedure. However, three patients experienced symptomatic 
and delayed recurrence of hydrothorax 16, 30, and 32 weeks 
after the initial procedure. Complications occurred were low 
grade fever/leukocytosis (n=11, 100.0%), pneumonia (n=1, 
9.1%), pneumothorax (n=4, 36.4%), azotemia/acute renal 
failure (n=6, 54.6%) and hepatic encephalopathy (n=4, 
36.4%). Chest pain and percutaneous drainage (PCD) site 
pain and chest pain occurred in all the 11 patients during the 
chemical pelurodesis. Five patients (45.5%) were suspected 
to have procedure-related mortality due to the occurrence of 
acute renal failure (Table 2).
DISCUSSION
This study was as retrospective observational results in 
the patients with refractory hydrothorax and cirrhosis. The 
current study adds a report of 11 patients to the previously 
published series of chemical pleurodesis
6-8 that examined 
the role of chemical pleurodesis with or without VATS for 
the management of refractory hepatic hydrothorax. The 
initial success of treatment was achieved in 8 of 11 patients 
(72.7%) which was comparable to the treatment result of 
previously published case series.
8 Notably, the cumulative 
survival rate was significantly higher in patients who 
achieved the initial success of treatment than patients 
without the initial success of treatment. The patients with 
initial treatment failure naturally underwent lesser sessions 
of chemical pleurodesis compared to the patients with 
successful treatment (albeit statistically insignificant) because 
the condition of a patient deteriorated, further session of Woo Jin Lee, et al. Pleurodesis for hepatic hydrothorax  295
   
   
Figure 1. Changes in the radiologic findings of the same patient prior to (A-C) and following (D-F) chemical pleurodesis. Prior to 
chemical pleurodesis, the chest PA (A), chest right decubitus (B), and chest CT scan (C) revealed a large amount of right pleural 
effusion. Four sessions of chemical pleuro-desis with talc were performed successfully, and the follow-up chest PA (D), chest right 
decubitus (E), and chest CT scan (F) performed 1  month after the last chemical pleurodesis revealed pleural thickening, but there 
was no fluid shifting in the right chest.
chemical pleurodesis could not be performed.
Ablation of the space between the parietal and visceral 
pleura with a sclerosing agent injected by tube thoracostomy 
has been used to treat hepatic hydrothorax.
3 The procedure is 
generally unsuccessful, probably because fluid is formed too 
rapidly to allow the visceral and parietal pleural surfaces to 
approximate and adhere.
6 Often, incomplete adhesions form 
between the parietal and visceral pleura, resulting in the 
formation of loculated pleural effusions. Thoracentesis does 
not evacuate all the fluid, because all locules cannot be 
aspirated. In addition, several complications may be associated 
with placement of a chest tube, including subcutaneous 
emphysema; lung, spleen, liver, and stomach laceration; 
unilateral pulmonary edema from rapid removal of fluid; 
and placement of the tube into the abdominal cavity. In the 
current study, complications associated with placement of a 
chest tube occurred in all enrolled patients, and most 
devastating complications were severe fluid and electrolytes 
imbalance and protein depletion leading the azotemia/acute 
renal failure. Five patients (45.5%) were suspected to have 
procedure-related mortality due to the occurrence of these 
devastating complications (Table 2). Milder complications 
such as fever/leucocytosis occurred in all enrolled patients, 
and a significant proportion of patients with refractory 
hepatic hydrothorax who had treated with chemical pleurodesis 
only via a chest tube and chemical pleurodesis+VATS 
experienced more severe complications such as pneumonia 
(n=1, 9.1%), pneumothorax (n=4, 36.4%), azotemia/acute 
renal failure (n=6, 54.6%) and hepatic encephalopathy (n=4, 
36.4%, Table 2). Morbidity including PCD site pain and 
chest pain during chemical pleurodesis occurred in all the 
patients. Because of low success rates and procedure- 
related complications, chest tube drainage of the pleural 
space for the routine treatment of hepatic hydrothorax is not 
recommended. However, the patients with advanced liver 
cirrhosis presenting with a unilateral pleural effusion, most 
commonly in the right side, usually present with symptoms 
related to shortness of breath, cough, hypoxemia and/or 
chest discomfort. Unlike the ascites, relief of symptoms and 
prevention of pulmonary complications and infections are 
critical for the patients with refractory hepatic hydrothorax 
who are potential candidates for liver transplantation. 
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Table 2. Treatment outcomes of chemical pleurodesis with or without VATS in patients with hepatic hydrothorax
No.
Age/
gender
Treatment
Success
*
(yes/no)
CTP 
class
Recurrence
(yes/no) 
Deceased
(yes/no)
Survival 
(days)
Complications
16 3 /
female
Chemical pleurodesis No C Yes Yes 22 Fever/leucocytosis
Pneumothorax
Acute renal failure
Hepatic encephalopathy
Liver failure
24 2 /
male
Chemical 
pleurodesis+VATS
Yes C Yes Yes 577 Fever/leucocytosis
Pneumothorax
Acute renal failure
Liver failure
37 1 /
female
Chemical pleurodesis No C Yes Yes 13 Fever/leucocytosis
Acute renal failure
Hepatic encephalopathy
Liver failure
46 3 /
male
Chemical pleurodesis Yes C No Yes 33 Fever/leucocytosis
Acute renal failure
Liver failure
55 7 /
male
Chemical pleurodesis Yes B No Yes 110 Fever/leucocytosis
Liver failure
66 3 /
female
Chemical 
pleurodesis+VATS
Yes C No Yes 98 Fever/leucocytosis
Pneumonia
GI bleeding
75 1 /
male
Chemical pleurodesis Yes C Yes Yes 153 Fever/leucocytosis
Liver failure
87 3 /
female
Chemical pleurodesis Yes C Yes No 212 Fever/leucocytosis
Pneumothorax
Acute renal failure
Hepatic encephalopathy
97 0 /
male
Chemical pleurodesis Yes B No No 363 Fever/leucocytosis
10 38/
male
Chemical pleurodesis Yes C No No 124 Fever/leucocytosis
Pneumothorax
11 84/
female
Chemical pleurodesis No C Yes Yes 20 Fever/leucocytosis
Acute renal failure
Hepatic encephalopathy
Liver failure
* Success of treatment was defined by a patient who had no longer dyspnea symptoms and had a chest roentgenogram that did not 
show pleural effusion at 1 month after the termination of VATS with chemical pleurodesis or chemical pleurodesis only. 
VATS, video-assisted thoracoscopic surgery; CTP, Child-Turcotte-Pugh.
Conventional treatment modalities for hepatic hydrothorax 
such as sodium restriction and diuretics, and intermittent 
thoracentesis cannot achieve the goals of treatment in many 
patients. Increasing the doses of diuretics to achieve the 
negative sodium balance may increase in the serum creatinine 
level, which indicates a decrease in the glomerular filtration 
rate.
9 Moreover, increasing the doses of diuretics may 
precipitate hepatic encephalopathy. Although, thoracentesis 
for hepatic hydrothorax in clinical practice is both useful and 
safe, thoracentesis dependence may be associated with 
deteriorating clinical status and impaired quality of life. 
Actually, when thoracentesis is required every 2-3 weeks, 
alternative strategies were needed to be considered.
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were reported to have encouraging results in patients of 
hepatic hydrothorax with or without ascites.
10-12 However, 
most of patients with TIPS for the treatment of hepatic 
hydrothorax developed hepatic encephalopathy and had 
the deterioration of liver function and subsequently died 
within 6 weeks of shunt placement.
12 Another study also 
evaluated the clinical efficacy of TIPS in patients with 
hepatic hydrothorax and this study reported poor prognosis 
in patients with hepatic hydrothorax who underwent TIPS.
13 
In our institution, TIPS was not available and we did not 
consider this treatment modality for our enrolled patients 
with refractory hepatic hydrothorax. Hence, we could not 
compare the treatment results between chemical pleurodesis 
with or without VATS and TIPS in patients with refractory 
hepatic hydrothorax.
There are a few reports of successful primary repair of 
diaphragmatic defects.
8,14 Evaluation for defects in the 
diaphragm formerly required a thoracotomy, which carries 
substantial risks. Recently, VATS was used to identify 
diaphragmatic defects in patients with refractory hepatic 
hydrothorax, and biologic glue or sutures were used to close 
the defects.
15 However, VATS also required a general 
anesthesia, which carries substantial risks for the patients 
with advanced liver cirrhosis. Additionally, in contrast to the 
series by Mouroux et al,
15 we did not identify any visible 
diaphragmatic defects in two patients who underwent 
chemical pelurodesis combined with VATS.
In a real clinical situation, where advanced liver cirrhosis 
patients with refractory hepatic hydrothorax who need 
symptomatic relief and the control of pulmonary complications 
are in the care of a physician who has a few available 
treatment modalities, chemical pleurodesis by tube thoracostomy 
may be a considerable treatment option for these intractable 
patients.
In the current study, success of treatment was identified as 
a significant prognostic indicator for patients with advanced 
liver cirrhosis and refractory hepatic hydrothorax. Previous 
study by Ferrante et al
8 also adopted the concept of success 
of treatment defined as control of symptomatic hydrothorax 
in the first 30 days after the VATS with talc pleurodesis. 
However, they did not figure out any prognostic significance 
of this concept “success of treatment”. However, in the 
current study, the patient who achieved the success of 
treatment showed significantly better outcomes than the 
patients who did not achieve the success of treatment.
The current study has limitations to consider. First, the 
number of enrolled patients with refractory hepatic 
hydrothorax is too small to draw any statistical significance. 
Due to the rare frequency of hepatic hydrothorax, previously 
reported case series
6-8 rarely included more than 20 patients 
with hepatic hydrothorax. Second, we could enroll only 2 
cases with chemical pleurodesis with VATS due to the 
practical and psychological burdens of general anesthesia in 
patients with decompensated liver diseases. Hence, we could 
not evaluate the clinical efficacy of chemical pleurodesis with 
VATS to reduce the performed sessions of pleurodesis 
compared to the procedure without VATS.
In summary, this series suggests that refractory hepatic 
hydrothorax can be controlled with multiple sessions of 
chemical pleurodesis via chest tube with or without VATS in 
as many as 72.7% of patients. Additionally, the patients who 
achieved the success of treatment defined as symptoms free 
and no pleural effusion at 1 month after the termination of 
chemical pleurodesis and/or VATS, showed significantly 
better outcomes than those who did not achieve the success 
of treatment. However, due to a significantly high occurrence 
rate of procedure-related morbidity and mortality hindered 
the routine application of this procedure for patients with 
this debilitating complication of end stage liver disease. 
Further options of management, such as TIPS or chemical 
pleurodesis combined with nasal continuous positive airway 
pressure (CPAP)
16 may be required for effective treatment 
for these patients. However, warrant future validation is 
needed.
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